StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $1.20 | $1.19 | -0.83% | 0.4M |
| 05-19 | $1.20 | $1.20 | +0.00% | 0.2M |
| 05-20 | $1.20 | $1.25 | +4.17% | 0.4M |
| 05-21 | $1.25 | $1.29 | +3.20% | 0.3M |
| 05-22 | $1.30 | $1.31 | +0.77% | 0.2M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
No sell-side coverage available for FLNA yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2013 2013-12-31 | Annual 2013 2013-09-30 | Annual 2013 2013-06-30 | Annual 2013 2013-03-31 |
|---|---|---|---|---|
Revenue | $41.12M | $1.96M | $1.96M | $1.96M |
Operating Income | $31.36M | $-1.54M | $-762.00K | $-443.00K |
Net Income | $31.54M | $-1.47M | $-709.00K | $-408.00K |
EPS (Diluted) | $0.70 | $-0.02 | $-0.01 | $-0.01 |
Total Assets | $50.10M | $51.76M | $53.20M | $54.87M |
Total Liabilities | $1.80M | $37.50M | $39.02M | $41.46M |
Cash & Equivalents | $48.59M | $49.73M | $51.55M | $51.59M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 45.51M | Not available | Not available | 44.93M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.